Left Bundle Branch Pacing Cuts Cardiomyopathy Risk by 67% Over Right Ventricular Pacing
A 160-patient RCT shows LBBP dramatically reduces pacing-induced cardiomyopathy and preserves heart function over 3 years.
Summary
For patients who rely heavily on cardiac pacemakers, where the pacing lead is placed matters enormously. This randomized trial compared left bundle branch pacing (LBBP), a newer physiological approach, against traditional right ventricular pacing (RVP) in 160 high-risk patients over three years. LBBP reduced the combined risk of death, heart failure hospitalization, and pacing-induced cardiomyopathy by nearly 70%. The benefit was driven mainly by a dramatic drop in pacing-induced cardiomyopathy — from 18% with RVP down to just 6.5% with LBBP. Patients receiving LBBP also showed meaningfully better heart pump function, smaller heart dimensions, and improved functional capacity. These findings suggest LBBP should be strongly considered as the preferred pacing strategy for patients at high risk of cardiac dysfunction.
Detailed Summary
Cardiac pacemakers save lives, but the conventional approach — right ventricular pacing (RVP) — carries a well-known downside: in patients who require frequent pacing, it can progressively weaken the heart, a condition called pacing-induced cardiomyopathy (PICM). Left bundle branch pacing (LBBP) is a newer technique that delivers electrical signals closer to the heart's natural conduction pathway, potentially preserving normal mechanical function. This trial is the first multicenter randomized controlled study to directly compare these two strategies in patients at elevated cardiac risk.
The LBBP-FAVOUR trial enrolled 160 patients with high pacing burden and elevated risk of cardiac dysfunction across multiple Chinese medical centers. Participants were randomized 1:1 to LBBP or RVP and followed for a median of 36 months. The primary composite endpoint included all-cause mortality, heart failure hospitalization, and PICM.
The results were striking. The primary composite endpoint occurred in only 11.6% of LBBP patients versus 33.9% of RVP patients — a 69% relative risk reduction. This was driven primarily by PICM, which occurred in 6.5% of LBBP patients versus 18.2% of RVP patients. All-cause mortality and heart failure hospitalization rates did not differ significantly between groups, likely due to the relatively small sample size and moderate follow-up duration.
Echocardiographic data reinforced the clinical findings. LBBP patients showed significantly better left ventricular ejection fraction (LVEF improved by an additional 5.34 percentage points), smaller left ventricular dimensions, and better NYHA functional class scores at 36 months — all indicating healthier, more efficient hearts.
Caveats include the relatively small sample size, single-country setting, and the fact that this summary is based on the abstract only. Larger international trials are needed to confirm these findings and guide broader clinical adoption of LBBP.
Key Findings
- LBBP reduced the composite endpoint of death, HF hospitalization, or PICM by 69% vs RVP over 36 months.
- Pacing-induced cardiomyopathy occurred in 6.5% of LBBP patients vs 18.2% of RVP patients.
- LBBP patients gained 5.34 additional LVEF percentage points compared to RVP at 36 months.
- Left ventricular dimensions were significantly smaller in LBBP group, indicating less cardiac remodeling.
- NYHA functional class was meaningfully better in LBBP patients at 3-year follow-up.
Methodology
Prospective, multicenter, randomized controlled trial enrolling 160 high pacing burden patients with elevated cardiac dysfunction risk, randomized 1:1 to LBBP or RVP. Median follow-up was 36 months. Primary endpoint was a composite of all-cause mortality, heart failure hospitalization, and pacing-induced cardiomyopathy.
Study Limitations
The trial enrolled only 160 patients across Chinese centers, limiting generalizability to broader populations. No significant differences were found in all-cause mortality or heart failure hospitalization, possibly due to underpowering for these endpoints. This summary is based on the abstract only, as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.